LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Bacterial Test Is Well-Suited for Mid-Sized Labs

By LabMedica International staff writers
Posted on 19 Jul 2018
Image: The iC-GPC gram-positive assay is a qualitative, multiplex test for the direct detection from positive blood cultures of five of the most common gram-positive bacteria responsible for bacterial bloodstream infections (Photo courtesy of iCubate).
Image: The iC-GPC gram-positive assay is a qualitative, multiplex test for the direct detection from positive blood cultures of five of the most common gram-positive bacteria responsible for bacterial bloodstream infections (Photo courtesy of iCubate).
Bacterial sepsis and its associated complications are a major cause of morbidity and the 10th leading cause of mortality in the USA. Early diagnosis and the institution of appropriate antimicrobial therapy are vital for favorable patient outcomes.

Traditional culture and antimicrobial susceptibility test methods are time dependent processes that often require two to four days before final test results are available. A recently developed assay is an accurate and reliable tool for the detection of the five most common gram-positive bacteria responsible for bloodstream infections.

A team of medical laboratory scientist from different institutions and led by the Laboratory Alliance of Central New York (Syracuse, NY, USA) collected and tested 1,134 patient blood culture clinical specimens from January 2015 until October 2016. Three different automated blood culture systems were evaluated: BacT/ALERT; BACTEC and VersaTREK. These were compared with the iC-GPC assay.

The iC-GPC gram-positive assay is a qualitative, multiplex test for the direct detection from positive blood cultures of five of the most common gram-positive bacteria responsible for bacterial bloodstream infections: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Enterococcus faecalis, and Enterococcus faecium. In the multicenter trial, involving testing on patient blood culture specimens that were positive for gram-positive cocci, the assay also detected the presence of mecA, vanA, and vanB resistance determinants.

The iC-GPC Assay had an overall percent agreement with the BC-GP assay of 95.5%. Discordant specimens were further analyzed by a polymerase chain reaction (PCR) and bidirectional sequencing method. The results indicate that the iC-GPC Assay together with the iCubate System is an accurate and reliable tool for the detection of the five most common gram-positive bacteria and their resistance markers responsible for bloodstream infections.

The authors concluded that the iC-GPC Assay provides a significantly more affordable alternative, particularly for small to medium-sized health care institutions, for the molecular detection of common gram-positive bacteria responsible for bloodstream infections and their resistance markers.

Paul A. Granato, PhD, Director of Microbiology and lead author of the study, said, “Traditional methods for the diagnosis or detection of what is causing bloodstream infections, such as septicemia, take two to five days to identify the bacterium and determine what type of antibiotic would be most appropriate for the treatment of a patient.” The study was originally published online on June 13, 2018, in the Journal of Clinical Microbiology.

Related Links:
Laboratory Alliance of Central New York

Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Silver Member
PCR Plates
Diamond Shell PCR Plates

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more